CRVO CervoMed Inc
Price (delayed)
$13.58
Market cap
$118.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.02
Enterprise value
$109.18M
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing
Highlights
CervoMed's EPS has shrunk by 146% YoY but it has increased by 7% QoQ
CervoMed's gross profit has increased by 36% YoY but it has decreased by 3.3% from the previous quarter
CRVO's net income is down by 36% QoQ
The company's quick ratio fell by 27% QoQ
Key stats
What are the main financial stats of CRVO
Market
Valuations
Earnings
Shares outstanding
8.7M
Market cap
$118.18M
Enterprise value
$109.18M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.86
Price to sales (P/S)
11.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.21
Revenue
$9.74M
Gross profit
$9.74M
Operating income
-$18.23M
Net income
-$16.29M
EBIT
-$16.29M
EBITDA
-$16.29M
Free cash flow
-$16.53M
Per share
Balance sheet
Liquidity
EPS
-$2.02
EPS diluted
-$2.02
Free cash flow per share
-$2.05
Book value per share
$4.75
Revenue per share
$1.21
TBVPS
$5.34
Total assets
$43.08M
Total liabilities
$3.88M
Debt
$0
Equity
$39.2M
Working capital
$39.2M
Debt to equity
0
Current ratio
11.11
Quick ratio
10.61
Net debt/EBITDA
0.55
Margins
Efficiency
Dividend
EBITDA margin
-167.3%
Gross margin
100%
Net margin
-167.3%
Operating margin
-187.2%
Return on assets
-42.5%
Return on equity
-46.5%
Return on invested capital
-60.9%
Return on capital employed
-41.6%
Return on sales
-167.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRVO stock price
How has the CervoMed stock price performed over time
Intraday
36.07%
1 week
76.13%
1 month
506.25%
1 year
-38.72%
YTD
480.34%
QTD
48.42%
Financial performance
How have CervoMed's revenue and profit performed over time
Revenue
$9.74M
Gross profit
$9.74M
Operating income
-$18.23M
Net income
-$16.29M
Gross margin
100%
Net margin
-167.3%
CRVO's operating income has dropped by 133% year-on-year and by 35% since the previous quarter
The operating margin has plunged by 71% YoY and by 40% from the previous quarter
The net margin has contracted by 41% from the previous quarter
CRVO's net income is down by 36% QoQ
Growth
What is CervoMed's growth rate over time
Valuation
What is CervoMed stock price valuation
P/E
N/A
P/B
2.86
P/S
11.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.21
CervoMed's EPS has shrunk by 146% YoY but it has increased by 7% QoQ
The P/B is 74% below the last 4 quarters average of 8.2 and 28% below the 5-year quarterly average of 2.9
The company's equity fell by 14% QoQ
The revenue rose by 36% YoY but it fell by 3.3% QoQ
The stock's price to sales (P/S) is 31% less than its last 4 quarters average of 11.9
Efficiency
How efficient is CervoMed business performance
The ROA has plunged by 174% YoY and by 7% from the previous quarter
The return on equity has dropped by 154% year-on-year and by 5% since the previous quarter
CervoMed's return on sales has decreased by 41% QoQ
The company's return on invested capital rose by 2.6% QoQ
Dividends
What is CRVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRVO.
Financial health
How did CervoMed financials performed over time
The current ratio has soared by 189% YoY but it has contracted by 26% from the previous quarter
The total liabilities has grown by 49% YoY and by 19% from the previous quarter
The debt is 100% less than the equity
The company's equity fell by 14% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.